Twist Bioscience (TWST) said Thursday it launched animal-origin-free and transfection-grade plasmid DNA preparation products for nucleic acid therapeutics research.
The new products are designed to meet specific quality needs for preclinical studies, including low or endotoxin-free requirements for work involving sensitive cells, according to Twist.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments